% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • theman111knows theman111knows Jan 25, 2013 9:30 PM Flag

    Cowen & Co. Raised SRPT to $55 Target Ahead Of Feb. Catalyst. More Upgrades Coming.

    $30's Next Week

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Upgrades only matter if they carry weight, from a house/analyst that big money follows. That's exactly what we got here. Fireworks a comin'. And I only care if more upgrades come from those who carry weight.

      Sentiment: Strong Buy

    • What catalysts are cropping up in Feb?

      Sentiment: Buy

      • 1 Reply to guru_essence
      • here is article Motley Fool
        A Look at Three Biotech Movers
        By Brian Nichols - January 25, 2013 | Tickers: CLSN, SRPT, THLD | 0 Comments
        Sarepta Therapeutics (NASDAQ: SRPT)
        I bought shares of Sarepta back in November at $25.50, and I wouldn’t sell them for $55 today. However, $55 is the exact target that Cowen & Cowen are giving the stock, as it prepares for its meeting with the FDA to determine a course of action for the development of its drug eterplirsen.
        . This is a stock that has been upgraded by virtually every analyst who covers the stock since announcing phase data for its Muscular Dystrophy drug back in October. The drug has been granted an Orphan status by the FDA and has the potential to reach prices in $100’s if approved.
        The real upside for this stock is not just the approval of its drug eterplirsen, but rather its technology, pipeline, and the Orphan status. The drug itself has peak sales expectations of about $700 million: I say this is a definite “buy."

12.35+0.62(+5.29%)Feb 12 4:00 PMEST